Latest news with #85thScientificSessions
Yahoo
20 hours ago
- Health
- Yahoo
Healthy.io, Geisinger and Boehringer Ingelheim Study Reveals Significant Increase in Albuminuria Identification with the Addition of Smartphone Technology
Longitudinal data highlight the significant impact of adding a novel home screening test to standard lab testing, increasing opportunities for earlier identification of disease and disease management. BOSTON, June 20, 2025 /PRNewswire/ -- a leader in transforming the smartphone camera into a medical device, Geisinger, one of the nation's leading providers of value-based care, and Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced data demonstrating the longitudinal impact of a novel chronic kidney disease (CKD) screening pilot program. The study, supported by Boehringer Ingelheim, included 4,000 patients from Geisinger with diabetes and/or hypertension, two prominent risk factors for CKD. Patients in the pilot group received either Minuteful Kidney™ smartphone-powered urine albumin-to-creatinine ratio (uACR) home test or a standard laboratory test, accompanied by patient outreach. The pilot group was compared to a 1:1 propensity-score-matched control group that received usual care (standard, routine healthcare services). Previously reported results revealed a significant 2.5-fold increase in uACR completion rates (53.1% vs. 21.2%, p<0.001) in the pilot group vs. control group. Findings presented at the American Diabetes Association (ADA) 85th Scientific Sessions on June 20, 2025, demonstrate that over a 270-day follow-up period, patients in the pilot group were more likely to receive a diagnosis related to CKD or proteinuria than those in the usual care arm (4.7% vs. 2.9%, p<0.001). Based on results of the Minuteful Kidney™ test, individuals with an elevated uACR (≥30 mg/g) were more likely to complete a primary care follow-up visit (95.3% vs. 92.9%, p<0.001) or a nephrology visit (7.2% vs. 1.7%, p<0.001) compared to those with a normal uACR (< 30 mg/g). Additionally, there were a higher proportion of new ACEi/ARB prescriptions (7.5% vs. 4.4%, p=0.024) or new SGLT2i prescriptions (4.1% vs. 2.7%, p=0.054) for individuals with elevated uACR (≥30 mg/g) compared to those with uACR <30mg/g, indicating the importance of identifying albuminuria. "Closing the uACR testing gap by reaching untested at-risk populations remains a top priority," said Geoff Martin, CEO of "These study results demonstrate how smartphone-enabled testing and education can enhance CKD screening compliance, which ultimately has the potential to improve patient outcomes. We value the collaboration with Geisinger and Boehringer Ingelheim as we work to close a care gap by supporting earlier identification of CKD through screening those identified as at risk of disease." "Detecting CKD early is crucial, as timely intervention can help mitigate the risk of disease progression and cardiovascular complications," said Brian DiDonato, Senior Vice President, Cardio-Renal-Metabolic Brands at Boehringer Ingelheim. "We are proud to support this important study of Minuteful Kidney program, which presents an innovative approach to address the urgent need for enhanced CKD screening." "uACR testing is critical for evaluating kidney health and risk of cardiovascular events such as myocardial infarction or stroke," said Alexander Chang, M.D., MS, Associate Professor from the Department of Population Health Sciences at Geisinger. "Given the increased rates of engagement, testing and follow-up care shown in this study, we are excited about the potential for the Minuteful Kidney program to drive earlier diagnosis rates and help make a direct, positive impact on patients' lives." Limited awareness of, and access to, comprehensive screenings often contribute to poorer outcomes, emphasizing the urgent need for innovative solutions. Minuteful Kidney is the only FDA-cleared, smartphone-enabled home uACR test for CKD, allowing patients to receive clinical-grade results within minutes. As a part of the pilot program, participants in the pilot group received education via the engagement team. For those completing the Minuteful Kidney test, the associated app provided additional education regarding testing and supported follow-up and results sharing with healthcare providers. The pilot program demonstrated how a home testing approach can complement and help remove barriers to care. About CKD CKD is a national health crisis that affects more than 35 million U.S. adults, increasing their risk for cardiovascular (CV) disease, kidney failure and dialysis. Yet approximately 90% of those with CKD are unaware that they have it, as it often has no symptoms until it progresses to more advanced stages. Clinical guidelines recommend routine screenings for at-risk individuals using both estimated glomerular filtration rate (eGFR) and uACR tests; however, broad adoption of these guidelines remains low. This testing gap hinders early detection of both kidney dysfunction and CV risk, as elevated uACR is associated with an increased risk of CV events, including myocardial infarction, stroke, hospitalization for heart failure and CV death. About transforms the smartphone camera into a medical device to deliver healthcare at the speed of life. The company's at-home urinalysis and digitized wound care services enable providers and healthcare systems to close gaps in access and care while increasing patient satisfaction. is a global leader in digital health and is a recipient of the 2023 MedTech Breakthrough 'Best In-Home Testing Solution' Award and the Juniper Research's Digital Health Innovation 'Best Digital Diagnostics Solution' 2023 Award. The company has offices in Boston, London and Tel-Aviv. About Geisinger Geisinger is among the nation's leading providers of value-based care, serving 1.2 million people in urban and rural communities across Pennsylvania. Founded in 1915 by philanthropist Abigail Geisinger, the nonprofit system generates $10 billion in annual revenues across 126 care sites — including 10 hospital campuses — and Geisinger Health Plan, with more than half a million members in commercial and government plans. Geisinger College of Health Sciences educates more than 5,000 medical professionals annually and conducts more than 1,400 clinical research studies. With 26,000 employees, including 1,700 employed physicians, Geisinger is among Pennsylvania's largest employers with an estimated economic impact of $15 billion to the state's economy. On March 31, 2024, Geisinger became the first member of Risant Health, a new nonprofit charitable organization created to expand and accelerate value-based care across the country. Learn more at or follow on Facebook, Instagram, LinkedIn and X. About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at Media Contact - info@ Logo - View original content to download multimedia: SOURCE Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
&w=3840&q=100)
Business Standard
2 days ago
- Health
- Business Standard
Stem cell breakthrough: New therapy raises hopes of curing type 1 diabetes
Living with type 1 diabetes is a constant battle where patients need to track blood sugar throughout the day and need insulin injections or pump-based therapies for life. But what if one day you could stop taking insulin for good? Today, it might sound impossible, but US-based scientists are working towards making it a reality. They have developed a new stem cell-derived treatment that has allowed the majority of patients with severe type 1 diabetes, who participated in the trial, to discontinue insulin use. The study titled Stem cell–derived, fully differentiated islets for Type 1 diabetes, published in The New England Journal of Medicine, tested an experimental treatment called zimislecel, developed by US biopharmaceutical company Vertex Pharmaceuticals. According to the research paper, it helped 83 per cent of participants achieve insulin independence and maintain stable blood sugar levels for at least one year, marking a potentially transformative step in diabetes care. What is zimislecel and what did the trial find? Researchers conducted a trial on 14 people with severe type 1 diabetes who suffered from hypoglycemic unawareness, a dangerous condition where blood sugar drops suddenly without warning signs. These patients are at risk of passing out, having seizures, or even dying from low blood sugar. According to the study, the participants received a stem cell-based infusion called zimislecel, which introduced lab-grown islet cells into their bodies. These new cells travelled to the liver and started working like natural insulin-producing cells. The findings show: 10 out of 12 surviving participants were able to completely stop using insulin within a year The remaining two patients needed significantly less insulin Patients spent over 70 per cent of their time within the healthy blood sugar range (70–180 mg/dL) Episodes of low blood sugar stopped within the first 90 days of treatment How zimislecel could change type 1 diabetes treatment According to the researchers, type 1 diabetes happens when the immune system mistakenly destroys insulin-producing islet cells in the pancreas. Without insulin, the body cannot regulate blood sugar levels, requiring lifelong insulin injections or pumps. Zimislecel changes this as it uses stem cells engineered to become islet cells, replacing what the immune system destroyed. Once inside the body, these cells settle in the liver and start regulating blood sugar like a healthy pancreas would. However, the participants in the trial also received glucocorticoid-free immunosuppressive therapy to prevent the body from attacking the newly introduced islet cells. This means that the patient might need to take immunosuppressants for life, which reduces immunity and increases the risk of infections. The study was presented at the American Diabetes Association's 85th Scientific Sessions held in Chicago from June 21–23. According to media reports, experts have cautioned that while this immunosuppression may be less risky than what's used for organ transplants, the long-term safety of zimislecel will need more years of follow-up. What's next for zimislecel and when could it be approved? Vertex Pharmaceuticals is now moving forward with phase 3 clinical trials of zimislecel. If larger studies confirm these results, the company may apply for approval from the US Food and Drug Administration (FDA) as early as next year. The cost of the treatment is still unknown, but experts agree that even the possibility of freedom from insulin is a groundbreaking leap forward. Can this stem cell therapy help with type 2 diabetes too? Zimislecel is currently being tested only in people with type 1 diabetes. Type 2 diabetes, which typically develops later in life and is related to insulin resistance rather than insulin absence, is a different disease that may not respond the same way to this therapy. However, other researchers are experimenting with procedures to cure type 2 diabetes through cell therapy. For example, scientists in China developed an artificial version of the insulin-producing cells found in the pancreas, which were then transplanted into the patient during trials that produced positive results. More research is going on in this regard to confirm the efficacy and safety of this approach before it can be widely used as a treatment. For more health updates, follow #HealthWithBS
Business Insider
2 days ago
- Business
- Business Insider
GlucoTrack Stock (GCTK) Stock Rockets 130% on Diabetes Tracking Data
GlucoTrack (GCTK) stock rocketed higher on Wednesday after the medical device company presented results from a clinical trial at the American Diabetes Association's (ADA) 85th Scientific Sessions. This study concerned its innovative blood-based continuous glucose monitoring technology and marked the first-in-human trial of the diabetes monitoring device. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter GlucoTrack shared that the clinical trial met its primary endpoint and all secondary endpoints, including a Mean Absolute Relative Difference of 7.7%, a 99% data capture rate, and no procedure or device-related serious adverse events. The company said it plans to start a long-term early feasibility study of the device in Q3 2025. The clinical trial results attracted the attention of traders on Wednesday, who sent shares of GCTK stock 129.63% higher this morning. That's a welcome change from the stock's year-to-date fall of 96.8% and 12-month drop of 99.75%. It also came with heavy trading, as 1.33 million shares changed hands, compared to a three-month daily average of 75,160 units. Is GlucoTrack Stock a Buy, Sell, or Hold? Wall Street doesn't offer significant coverage of GlucoTrack stock. Luckily, TipRanks' AI analyst Spark does. It rates GCTK as an Underperform (28) with no price target. Spark cites 'poor financial performance, characterized by a lack of revenue and negative equity' as reasons for the rating.
Yahoo
3 days ago
- Health
- Yahoo
Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
ENT-03 was safe and well tolerated at all evaluated doses, with positive efficacy trends DOYLESTOWN, Pa., June 25, 2025--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced top-line data from a Phase 1a clinical trial of its drug candidate, ENT-03, in obese and diabetic patients. ENT-03 was found to be safe and well tolerated at all doses evaluated as presented at the American Diabetes Association 85th Scientific Sessions on June 22, 2025. The study results showed positive trends for both weight reduction and increased insulin sensitivity at higher tested doses. ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose, improves insulin sensitivity, and causes weight loss by acting on brain circuits that regulate energy and metabolism. In addition to the clinical trial results, ENT-03 is effective as a monotherapy and has an additive effect in combination with GLP1 agonists in animal models. ENT-03 also demonstrates durable weight loss and glucose and insulin normalization after therapy cessation. "Our first-in-human study has demonstrated that ENT-03 is safe and very well tolerated and showed positive trends in both weight loss and insulin sensitivity that are consistent with what we have seen in preclinical in vivo studies," said Richard Larson, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of Metabolics Pharma. "We are planning a Phase 1b study to evaluate dosing regimens, which we expect to initiate in the second half of 2025." The Phase 1a clinical trial was a single ascending dose study evaluating seven dose cohorts of ENT-03 in healthy obese subjects and obese subjects with type 2 diabetes (T2D). ENT-03 was administered subcutaneously (SQ) at six different doses. The primary endpoint was safety and tolerability and pharmacokinetic data. Secondary endpoints included fasting blood glucose, fasting insulin, lipid levels, and change in body weight at 7 days. More information can be found on ENT-03 was very well tolerated and efficacy endpoints showed trends toward weight loss at higher doses for both obese and obese/T2D subjects, along with improvement in insulin sensitivity. About Metabolics PharmaMetabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity, type 2 diabetes, and MASH. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit View source version on Contacts Company contact: Richard Larson, M.D., Executive Officer, Chief Medical Officer, and Chairman of the BoardJohn DessoukiChief Financial
Yahoo
3 days ago
- Health
- Yahoo
Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
ENT-03 was safe and well tolerated at all evaluated doses, with positive efficacy trends DOYLESTOWN, Pa., June 25, 2025--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced top-line data from a Phase 1a clinical trial of its drug candidate, ENT-03, in obese and diabetic patients. ENT-03 was found to be safe and well tolerated at all doses evaluated as presented at the American Diabetes Association 85th Scientific Sessions on June 22, 2025. The study results showed positive trends for both weight reduction and increased insulin sensitivity at higher tested doses. ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose, improves insulin sensitivity, and causes weight loss by acting on brain circuits that regulate energy and metabolism. In addition to the clinical trial results, ENT-03 is effective as a monotherapy and has an additive effect in combination with GLP1 agonists in animal models. ENT-03 also demonstrates durable weight loss and glucose and insulin normalization after therapy cessation. "Our first-in-human study has demonstrated that ENT-03 is safe and very well tolerated and showed positive trends in both weight loss and insulin sensitivity that are consistent with what we have seen in preclinical in vivo studies," said Richard Larson, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of Metabolics Pharma. "We are planning a Phase 1b study to evaluate dosing regimens, which we expect to initiate in the second half of 2025." The Phase 1a clinical trial was a single ascending dose study evaluating seven dose cohorts of ENT-03 in healthy obese subjects and obese subjects with type 2 diabetes (T2D). ENT-03 was administered subcutaneously (SQ) at six different doses. The primary endpoint was safety and tolerability and pharmacokinetic data. Secondary endpoints included fasting blood glucose, fasting insulin, lipid levels, and change in body weight at 7 days. More information can be found on ENT-03 was very well tolerated and efficacy endpoints showed trends toward weight loss at higher doses for both obese and obese/T2D subjects, along with improvement in insulin sensitivity. About Metabolics PharmaMetabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity, type 2 diabetes, and MASH. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit View source version on Contacts Company contact: Richard Larson, M.D., Executive Officer, Chief Medical Officer, and Chairman of the BoardJohn DessoukiChief Financial
